{
  "figure_1": "Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.",
  "figure_2": "Geographical distribution of the included breast cancer screening guidelines.",
  "figure_3": "Quality of the included guidelines for the six domains of the AGREE Ⅱ instrument.\n(Abbreviations: ACOG: American College of Obstetricians and Gynecologists; ACP: American College of Physicians; ACR: American College of Radiology; ACS: American Cancer Society; AWMF: German Association of Scientific Medical Societies; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; CTFPHC: Canadian Task Force on Preventive Health Care; ECIBC: European Commission Initiative on Breast Cancer; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; MOH: Ministry of Health; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; SBI: Society of Breast Imaging; USPSTF: U.S. Preventive Services Task Force; WHO: World Health Organization).",
  "figure_4": "The main screening recommendations in average-risk women in the eligible guidelines.\n(Abbreviations: CBE: Clinical Breast Examination; MAM: Mammography; US: Ultrasound)",
  "figure_5": "The main screening recommendations in high-risk women in the eligible guidelines.\n(Abbreviations: BSE: Breast Self Examination; CBE: Clinical Breast Examination; MAM: Mammography; MRI: Magnetic Resonance Imaging; NR: No Recommendation; US: Ultrasound)"
}